Cassava Sciences Announces Positive Top-Line Clinical Results in Phase II Study Evaluating Simufilam in Alzheimer’s Disease
Cassava Sciences, Inc. announced positive top-line Phase II results for simufilam, its oral drug candidate for Alzheimer’s disease dementia. The study enrolled over 200 patients with mild-to-moderate Alzheimer’s disease.
[British Journal of Cancer] The immunoproteasome subunit LMP7 was silenced by using gene knockout or inhibited by the epoxyketone inhibitor ONX 0914 in a mouse castration-resistant prostate cancer (CRPC) tumor graft model and in interferon-γ-pretreated human CRPC cell lines in vitro.
[British Journal of Cancer] 582 mCRPC patients undergoing first-line abiraterone therapy from four institutions were sorted by three phases: discovery, training, and validation.
[International Journal of Radiation Oncology*Biology*Physics] Researchers performed an international multi-institutional retrospective study of 277 men with metachronous oligometastatic castration-sensitive prostate cancer who underwent targeted DNA sequencing of their primary/metastatic tumor.